Pancreatic cancer is a disease in which cells in the pancreas grow out of control, forming tumors that interfere with digestion and blood sugar regulation. It is one of the most aggressive cancers: more than half of cases are already metastatic at diagnosis, and the overall five-year survival rate remains among the lowest of any cancer type. Understanding the disease, its warning signs, and how it’s treated can help you recognize problems early and make sense of what comes next.
What the Pancreas Does
The pancreas is a six-inch organ tucked behind your stomach. It has two jobs. Its exocrine cells produce digestive enzymes that break down fats, proteins, and carbohydrates in your small intestine. Its endocrine cells, clustered in tiny groups called islets, release insulin and other hormones that control blood sugar. When a tumor grows in the pancreas, it can destroy the surrounding tissue and disrupt both functions. Many people with pancreatic cancer develop new-onset diabetes as an early consequence, because the tumor interferes with insulin-producing cells. Others lose the ability to digest food properly, leading to weight loss and nutrient deficiencies.
Types of Pancreatic Tumors
About 95% of pancreatic cancers are ductal adenocarcinomas, meaning they start in the cells lining the ducts that carry digestive enzymes. These tumors tend to have poor blood supply, grow aggressively, and spread early. When people refer to “pancreatic cancer” without further detail, this is almost always what they mean.
The remaining 2% to 10% are pancreatic neuroendocrine tumors (NETs), which arise from hormone-producing cells in the organ’s tissue rather than the ducts. NETs are typically slower-growing and more vascular, and they often respond better to treatment. The distinction matters because the two types behave very differently and require different approaches.
Symptoms to Watch For
Pancreatic cancer is notoriously difficult to catch early because the pancreas sits deep in the abdomen, and small tumors rarely cause noticeable problems. By the time symptoms appear, the disease has often advanced. The most common signs include:
- Jaundice: Yellowing of the skin and whites of the eyes, often without pain. This happens when a tumor in the head of the pancreas blocks the bile duct. You may also notice dark urine, pale or floating stools, and intense itching.
- Abdominal or back pain: A dull ache in the upper belly that radiates to the sides or mid-back. This can worsen after eating or when lying down.
- Unexplained weight loss and appetite loss: The body struggles to digest food properly, and cancer itself increases calorie demands.
- New or worsening diabetes: A sudden diabetes diagnosis in someone over 50, or existing diabetes that becomes unusually hard to control, can be an early signal.
- Blood clots: Pain and swelling in an arm or leg from a deep vein clot is sometimes the first indication of pancreatic cancer.
- Fatigue: Persistent tiredness that doesn’t improve with rest.
None of these symptoms is unique to pancreatic cancer, which is part of the challenge. But jaundice combined with unexplained weight loss or new diabetes in a middle-aged or older adult warrants prompt investigation.
Who Is Most at Risk
Smoking is the single most important modifiable risk factor. People who smoke are roughly twice as likely to develop pancreatic cancer as those who never have, and about 25% of all cases are attributed to cigarette smoking. Obesity raises risk by about 20%. Chronic pancreatitis, a condition of long-term inflammation in the pancreas, is also strongly linked.
Age plays a major role on the non-modifiable side. Almost all patients are older than 45, about two-thirds are at least 65, and the average age at diagnosis is 70. Men are slightly more likely to be diagnosed than women, and African Americans face a somewhat higher risk than white Americans.
Inherited genetic mutations account for roughly 10% of pancreatic cancers. Families with mutations in genes like BRCA1, BRCA2, PALB2, CDKN2A, or STK11 carry elevated risk. If you have two or more blood relatives who have had pancreatic cancer, or if you carry one of these known mutations, screening programs may apply to you.
How It’s Diagnosed
Diagnosis typically begins with imaging. CT scans are the standard first step, giving doctors a detailed view of the tumor’s size and whether it has spread to nearby blood vessels. MRI provides additional detail in certain cases. Endoscopic ultrasound, in which a small probe is guided through the stomach to get close to the pancreas, can detect smaller tumors and allow for tissue biopsy at the same time.
A blood marker called CA 19-9 is sometimes measured, but it has significant limitations. In symptomatic patients, it picks up pancreatic cancer about 79% to 81% of the time, but its positive predictive value in the general population is extremely low (under 1%), making it useless as a screening tool for people without symptoms. It can also give false negatives in the 5% to 10% of people who lack a specific blood antigen, and false positives in people with bile duct blockages. Where CA 19-9 does prove useful is in monitoring. After surgery or chemotherapy, rising levels can signal recurrence two to six months before it shows up on scans, and dropping levels suggest the treatment is working.
Staging and Whether Surgery Is Possible
The most critical question at diagnosis is whether the tumor can be surgically removed. Doctors classify pancreatic tumors into three categories based on how much the cancer involves nearby blood vessels:
- Resectable: The tumor has no contact with major arteries and only limited involvement of nearby veins. Surgery is the primary option.
- Borderline resectable: The tumor touches arteries or veins to a moderate degree. Chemotherapy before surgery may shrink it enough to operate.
- Locally advanced (unresectable): The tumor extensively encases major blood vessels. Surgery to remove it is not feasible, though other treatments can help control it.
Only about 15% of pancreatic cancers are still confined to the pancreas at diagnosis. Another 28% have spread to nearby lymph nodes. The majority, 51%, have already metastasized to distant organs like the liver or lungs.
Survival Rates by Stage
Five-year survival varies dramatically depending on how far the cancer has spread at the time of diagnosis, according to National Cancer Institute data covering 2015 through 2021. For localized disease (confined to the pancreas), the five-year relative survival is 43.6%. Once it has spread to regional lymph nodes, that drops to 16.7%. For distant metastatic disease, the figure is 3.2%. These numbers reflect averages across all patients and treatments, so individual outcomes can differ, but they illustrate why early detection matters so much.
Treatment Options
For tumors that can be surgically removed, the standard operation for cancers in the head of the pancreas is the Whipple procedure, which removes the head of the pancreas along with parts of the small intestine, bile duct, and sometimes a portion of the stomach. It is a major operation with a significant recovery period, but it offers the best chance at long-term survival. Roughly 20% of patients who undergo a complete Whipple resection achieve long-term survival.
Most patients receive chemotherapy either before surgery (to shrink the tumor) or after (to reduce recurrence risk), and often both. For advanced or inoperable disease, combination chemotherapy regimens have shown meaningful survival improvements over older single-drug approaches. One common regimen extended median survival from about 6.8 months to 11.1 months in a landmark trial of 342 patients with advanced disease. Another combination improved median survival from 6.7 to 8.5 months. These gains may sound modest in absolute terms, but they represented significant progress for a cancer that had long resisted treatment.
Targeted Therapies on the Horizon
A genetic mutation called KRAS is present in up to 90% of pancreatic ductal adenocarcinomas, making it a prime target. The problem has been that the most common forms of this mutation in pancreatic cancer (known as G12D and G12V) could not be directly targeted by existing drugs. The few KRAS-blocking drugs approved for lung cancer work only against a variant called G12C, which appears in just 2% to 3% of pancreatic cancers.
That is beginning to change. A new inhibitor designed specifically for the G12D mutation showed tumor shrinkage of more than 30% in 73% of pancreatic cancer models tested in the lab and has entered early-stage clinical trials. Other drugs targeting a protein that activates all forms of KRAS are also being tested. These approaches are still experimental, but they represent the first realistic attempts to hit the mutation that drives most pancreatic cancers.
Screening for High-Risk Individuals
There is no routine screening test for pancreatic cancer in the general population, and current blood markers are not accurate enough to fill that role. Screening is reserved for people at substantially elevated risk: those carrying mutations in genes like BRCA2, PALB2, CDKN2A, or STK11, and those with two or more first-degree relatives who have had the disease.
For these individuals, annual surveillance using MRI or endoscopic ultrasound typically begins at age 50, or 10 years before the youngest affected relative was diagnosed, whichever comes first. People with certain higher-risk genetic syndromes, such as familial atypical mole-melanoma syndrome or Peutz-Jeghers syndrome, are advised to start screening earlier, around age 35 to 40, sometimes at six-month intervals rather than annually. The goal is to catch tumors while they are still localized and operable, when the five-year survival rate is more than ten times higher than for metastatic disease.